Antiphospholipid antibodies: Lessons from the bench

Journal of Autoimmunity 28, 129-133 DOI: 10.1016/j.jaut.2007.02.009

Citation Report

#	Article	IF	CITATIONS
1	Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: Implications on the development of antiphospholipid syndrome. Journal of Autoimmunity, 2007, 29, 164-173.	6.5	51
2	Natural antibodies and cancer. Journal of Autoimmunity, 2007, 29, 295-302.	6.5	85
3	The role of the innate immune response in autoimmune disease. Journal of Autoimmunity, 2007, 29, 206-212.	6.5	95
4	Antiphospholipid syndrome: new light comes from in vivo studies. Journal of Thrombosis and Haemostasis, 2007, 5, 1825-1827.	3.8	3
5	Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmunity Reviews, 2007, 7, 46-51.	5.8	35
6	One year in autoimmunity. Autoimmunity Reviews, 2007, 7, 85-93.	5.8	8
8	APS—More Systemic Disease than SLE. Clinical Reviews in Allergy and Immunology, 2007, 32, 129-130.	6.5	20
9	Smoking Cessation: Significance and Implications for Children. Clinical Reviews in Allergy and Immunology, 2008, 34, 231-249.	6.5	3
10	Systemic Lupus Erythematosus Involving the Nervous System: Presentation, Pathogenesis, and Management. Clinical Reviews in Allergy and Immunology, 2008, 34, 356-360.	6.5	41
11	Anti-Mitochondrial Antibody–Negative Primary Biliary Cirrhosis. Clinics in Liver Disease, 2008, 12, 173-185.	2.1	32
12	Autoantibody explosion in antiphospholipid syndrome. Journal of Autoimmunity, 2008, 30, 74-83.	6.5	87
13	Pathogenesis of the antiphospholipid syndrome: An additional example of the mosaic of autoimmunity. Journal of Autoimmunity, 2008, 30, 99-103.	6.5	68
14	Controversies and Unresolved Issues in Antiphospholipid Syndrome Pathogenesis and Management. Hematology/Oncology Clinics of North America, 2008, 22, 155-174.	2.2	13
15	Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus, 2008, 17, 872-877.	1.6	24
16	Genomics and proteomics: a new approach for assessing thrombotic risk in autoimmune diseases. Lupus, 2008, 17, 905-916.	1.6	7
17	Arteriosclerosis obliterans associated with anti-cardiolipin antibody / Â2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. Rheumatology, 2008, 47, 684-689.	1.9	24
18	The Influence of the 1997 Updated Classification Criteria for Systemic Lupus Erythematosus: Epidemiology, Disease Presentation, and Patient Management. Journal of Rheumatology, 2009, 36, 552-559.	2.0	34
19	<i>In Vitro</i> Effects of Antiphospholipid Syndromeâ€lgG Fractions and Human Monoclonal Antiphospholipid IgG Antibody on Human Umbilical Vein Endothelial Cells and Monocytes. Annals of the New York Academy of Sciences. 2009. 1173. 805-813.	3.8	20

CITATION REPORT

#	Article	IF	CITATIONS
20	Effects of Lowâ€Molecularâ€Weight Heparin on Adhesion and Vesiculation of Phospholipid Membranes. Annals of the New York Academy of Sciences, 2009, 1173, 874-886.	3.8	25
21	Antiphospholipid Syndrome. Progress in Cardiovascular Diseases, 2009, 52, 115-125.	3.1	60
22	Pregnancy and Catastrophic Antiphospholipid Syndrome. Clinical Reviews in Allergy and Immunology, 2009, 36, 85-90.	6.5	25
23	Microthrombotic/Microangiopathic Manifestations of the Antiphospholipid Syndrome. Clinical Reviews in Allergy and Immunology, 2009, 36, 109-125.	6.5	30
24	Catastrophic Antiphospholipid Syndrome: Treatment, Prognosis, and the Risk of Relapse. Clinical Reviews in Allergy and Immunology, 2009, 36, 80-84.	6.5	44
25	Novel biomarkers of atherosclerosis and cardiovascular risk in autoimmune diseases: Genomics and proteomics approaches. Proteomics - Clinical Applications, 2009, 3, 213-225.	1.6	10
26	The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: Compelling evidence. Journal of Autoimmunity, 2009, 32, 1-6.	6.5	71
28	Mode of Interaction between β2GPI and Lipoprotein Receptors Suggests Mutually Exclusive Binding of β2GPI to the Receptors and Anionic Phospholipids. Structure, 2010, 18, 366-376.	3.3	27
29	Endocardite de Libman-Sacks, anticorpos antifosfolÃpides e trombose arterial no lúpus ertitematoso sistêmico: relato de caso. Revista Brasileira De Reumatologia, 2010, 50, 716-719.	0.8	2
30	The Pathophysiology of the Catastrophic Antiphospholipid Syndrome: Compelling Evidence. Clinical Reviews in Allergy and Immunology, 2010, 39, 207-207.	6.5	0
31	Advantages of Multiplex Proteomics in Clinical Immunology. Clinical Reviews in Allergy and Immunology, 2011, 41, 20-35.	6.5	20
32	Immunogenicity and pharmacokinetic studies of recombinant Factor VIII containing lipid cochleates. Drug Delivery, 2011, 18, 246-254.	5.7	8
34	Anti-phospholipid antibodies contribute to arteriosclerosis in patients with systemic lupus erythematosus through induction of tissue factor expression and cytokine production from peripheral blood mononuclear cells. Thrombosis Research, 2012, 130, 667-673.	1.7	24
35	Potential Use of Statins in the Treatment of Antiphospholipid Syndrome. Current Rheumatology Reports, 2012, 14, 87-94.	4.7	28
36	Common Acquired Causes of Thrombosis in Children. Current Problems in Pediatric and Adolescent Health Care, 2013, 43, 169-177.	1.7	14
37	Antiphospholipid antibodies-associated diffuse alveolar hemorrhage. Seminars in Arthritis and Rheumatism, 2015, 44, 652-657.	3.4	25
38	Clinical Manifestations. , 2016, , 503-508.		0
39	Anti-phospholipid Antibodies and Smoking: An Overview. Clinical Reviews in Allergy and Immunology, 2017, 53, 1-13.	6.5	20

#	ARTICLE	IF	CITATIONS
40	Clinical manifestations. , 2021, , 575-581.		0
41	Diseases of the Immune System. , 2010, , 183-257.		5
42	A Novel Dimeric Inhibitor Targeting Beta2GPI in Beta2GPI/Antibody Complexes Implicated in Antiphospholipid Syndrome. PLoS ONE, 2010, 5, e15345.	2.5	27
43	What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Thrombosis?. , 2012, , 57-78.		0
44	What is the Origin of Antiphospholipid Antibodies?. , 2012, , 23-39.		0
45	Pathogenetic mechanisms of antiphospholipid antibody production in antiphospholipid syndrome. World Journal of Rheumatology, 2015, 5, 59.	0.5	0
46	Diseases of the Immune System. , 0, , 112-112.		2